Phase III
The trial’s primary endpoint was to assess endometrial health, with additional goals of evaluating the safety and tolerability of the drug.
Agenus and Targovax partner on a KRAS cancer vaccine, Elixirgen and Taisho target aging and Tonix and Mass General team up again to fight kidney transplant rejection.
Gilead Sciences posted some good news: a late-stage study of its antibody-drug conjugate Trodelvy shows promise in slowing the progression of the most common forms of breast cancer.
OptiNose AS announced that its Phase III ReOpen1 clinical trial met both of its co-primary endpoints. It will be used to treat patients diagnosed with chronic sinusitis.
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
ABVC Biopharma, based in California, has programs in Phase II trials to treat major depressive disorder, adult attention deficit hyperactivity disorder and myelodysplastic syndrome.
Shares of NuCana have plunged more than 57% in premarket trading after the company announced its Phase III biliary tract cancer study. See more facts here.
The clinical trial, called SKYLINE, is starting without results from other key ongoing studies on the drug.
In the Phase III MELODY trial, researchers found a 74.5% lower incidence of respiratory syncytial virus-caused pneumonia, and bronchiolitis. Here’s more about it.
The FDA has not yet issued any hold orders to Cassava, but the company expects that its time is coming after rivals Denali and Cortexyme received theirs.
PRESS RELEASES